vs
MATERION Corp（MTRN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是MATERION Corp的1.4倍（$772.1M vs $549.8M），Revvity净利率更高（12.7% vs 3.5%，领先9.2%），MATERION Corp同比增速更快（30.8% vs 5.9%），过去两年MATERION Corp的营收复合增速更高（13.6% vs 9.0%）
Materion是一家专注于高性能先进材料领域的跨国企业，核心产品涵盖先进铍金属、薄膜沉积材料、高性能合金及复合材料、特种工程铍、工程金属、工业陶瓷、钽、铌等各类贵金属与非贵金属，同时提供无机化学品及特种涂层解决方案，广泛应用于高端制造领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MTRN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$549.8M
营收增速更快
MTRN
高出25.0%
5.9%
净利率更高
RVTY
高出9.2%
3.5%
两年增速更快
MTRN
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $549.8M | $772.1M |
| 净利润 | $19.4M | $98.4M |
| 毛利率 | 14.9% | — |
| 营业利润率 | 5.1% | 14.5% |
| 净利率 | 3.5% | 12.7% |
| 营收同比 | 30.8% | 5.9% |
| 净利润同比 | 9.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTRNRVTY
| Q1 26 | $549.8M | — | ||
| Q4 25 | $489.8M | $772.1M | ||
| Q3 25 | $444.8M | $698.9M | ||
| Q2 25 | $431.7M | $720.3M | ||
| Q1 25 | $420.3M | $664.8M | ||
| Q4 24 | $436.9M | $729.4M | ||
| Q3 24 | $436.7M | $684.0M | ||
| Q2 24 | $425.9M | $691.7M |
净利润MTRNRVTY
| Q1 26 | $19.4M | — | ||
| Q4 25 | $6.6M | $98.4M | ||
| Q3 25 | $25.4M | $46.7M | ||
| Q2 25 | $25.1M | $53.9M | ||
| Q1 25 | $17.7M | $42.2M | ||
| Q4 24 | $-48.9M | $94.6M | ||
| Q3 24 | $22.3M | $94.4M | ||
| Q2 24 | $19.0M | $55.4M |
毛利率MTRNRVTY
| Q1 26 | 14.9% | — | ||
| Q4 25 | 13.0% | — | ||
| Q3 25 | 19.4% | 53.6% | ||
| Q2 25 | 19.1% | 54.5% | ||
| Q1 25 | 18.1% | 56.5% | ||
| Q4 24 | 21.3% | — | ||
| Q3 24 | 18.5% | 56.3% | ||
| Q2 24 | 19.0% | 55.7% |
营业利润率MTRNRVTY
| Q1 26 | 5.1% | — | ||
| Q4 25 | 2.2% | 14.5% | ||
| Q3 25 | 7.9% | 11.7% | ||
| Q2 25 | 8.5% | 12.6% | ||
| Q1 25 | 6.5% | 10.9% | ||
| Q4 24 | -8.8% | 16.3% | ||
| Q3 24 | 7.2% | 14.3% | ||
| Q2 24 | 7.5% | 12.4% |
净利率MTRNRVTY
| Q1 26 | 3.5% | — | ||
| Q4 25 | 1.3% | 12.7% | ||
| Q3 25 | 5.7% | 6.7% | ||
| Q2 25 | 5.8% | 7.5% | ||
| Q1 25 | 4.2% | 6.4% | ||
| Q4 24 | -11.2% | 13.0% | ||
| Q3 24 | 5.1% | 13.8% | ||
| Q2 24 | 4.5% | 8.0% |
每股收益（稀释后）MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $0.30 | $0.86 | ||
| Q3 25 | $1.22 | $0.40 | ||
| Q2 25 | $1.21 | $0.46 | ||
| Q1 25 | $0.85 | $0.35 | ||
| Q4 24 | $-2.34 | $0.77 | ||
| Q3 24 | $1.07 | $0.77 | ||
| Q2 24 | $0.91 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.2M | $919.9M |
| 总债务越低越好 | $489.9M | — |
| 股东权益账面价值 | $957.0M | $7.3B |
| 总资产 | $1.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.51× | — |
8季度趋势，按日历期对齐
现金及短期投资MTRNRVTY
| Q1 26 | $16.2M | — | ||
| Q4 25 | $13.7M | $919.9M | ||
| Q3 25 | $16.4M | $931.4M | ||
| Q2 25 | $12.6M | $991.8M | ||
| Q1 25 | $15.6M | $1.1B | ||
| Q4 24 | $16.7M | $1.2B | ||
| Q3 24 | $17.9M | $1.2B | ||
| Q2 24 | $17.1M | $2.0B |
总债务MTRNRVTY
| Q1 26 | $489.9M | — | ||
| Q4 25 | $460.6M | — | ||
| Q3 25 | $458.9M | — | ||
| Q2 25 | $427.6M | — | ||
| Q1 25 | $453.0M | — | ||
| Q4 24 | $443.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MTRNRVTY
| Q1 26 | $957.0M | — | ||
| Q4 25 | $943.3M | $7.3B | ||
| Q3 25 | $934.6M | $7.4B | ||
| Q2 25 | $910.6M | $7.6B | ||
| Q1 25 | $887.9M | $7.6B | ||
| Q4 24 | $868.9M | $7.7B | ||
| Q3 24 | $931.9M | $7.9B | ||
| Q2 24 | $907.1M | $7.9B |
总资产MTRNRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.9B | $12.8B | ||
| Q2 24 | $1.8B | $13.4B |
负债/权益比MTRNRVTY
| Q1 26 | 0.51× | — | ||
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $19.5M | $182.0M | ||
| Q3 25 | $18.3M | $138.5M | ||
| Q2 25 | $49.9M | $134.3M | ||
| Q1 25 | $15.5M | $128.2M | ||
| Q4 24 | $76.3M | $174.2M | ||
| Q3 24 | $5.1M | $147.9M | ||
| Q2 24 | $20.3M | $158.6M |
自由现金流MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $3.2M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $-24.3M | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 0.8% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | -5.6% | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 2.9% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 6.7% | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率MTRNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.97× | 1.85× | ||
| Q3 25 | 0.72× | 2.97× | ||
| Q2 25 | 1.99× | 2.49× | ||
| Q1 25 | 0.88× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 0.23× | 1.57× | ||
| Q2 24 | 1.07× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTRN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
